Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to α vβ 3 integrin

Molecular Cancer Research

Volumn 2, Issue 12, 2004, Pages 663-673

  Dickerson, Erin B ^a   Akhtar, Nasim ^a   Steinberg, Howard ^a   Wang, Zun Yi ^a   Lindstrom, Mary J ^b,d   Padilla, Marcia L ^a   Auerbach, Robert ^c,d   Helfand, Stuart C ^a,b,d  

^a School of Veterinary Medicine   (United States)

^b Dept of Biostat and Med Inform ^*  (United States)

^c Laboratory of Developmental Biology   (Greece)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; BETA3 INTEGRIN; CYSTEINYLASPARTYLCYSTEINYLARGINYLGLYCYLASPARTYLCYSTEINYLPHENYLALANYLCYSTEIN AMIDE; CYTOKINE; GAMMA INTERFERON; HYBRID PROTEIN; MURINE RECOMBINANT INTERLEUKIN 12VP; PEPTIDE DERIVATIVE; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG; VASCULAR HOMING PEPTIDE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SPECIFICITY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORNEA; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; KNOCKOUT MOUSE; LIGAND BINDING; LIVER NECROSIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; FLOW CYTOMETRY; INTEGRIN ALPHAVBETA3; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, KNOCKOUT; MICE, TRANSGENIC; NECROSIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDES; PLASMIDS; PROTEIN ENGINEERING; PROTEIN ISOFORMS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-12; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

ANIMALIA; MURINAE;

EID: 12744274648     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects of human lymphocytes. J Exp Med 1989;170:827-45.
2. Chan S, Perussia B, Gupta JW, et al. Induction of IFN-γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991;173:869-79.
3. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993;178:1223-30.
4. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994;153:1697-706.
5. Dias S, Thomas H, Balkwill F. Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy or a murine breast cancer model. Int J Cancer 1998;75:151-7.
6. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, DAmato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
7. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol 1996;106:1114-8.
8. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-82.
9. Sgadari C, Farber JM, Angiolillo AL, et al. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 1997;89:2635-43.
10. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997;90:2541-8.
11. Bajetta E, Del Vecchio M, Mortarini R, et al. Pilot Study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 1998;4:75-85.
12. Jia SF, Worth LL, Densmore CL, et al. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res 2003;9:3462-8.
13. Sabel MS, Skitzki J, Stoolman L, et al. Intratumoral IL-12 and TNF-α-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol 2004;11:147-56.
14. Sangro B, Mazzolini G, Ruiz J, et al. Phase 1 trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004;22:1389-97.
15. Davis GE. Affinity of integrins for damaged extracelluar matrix: avb3 binds to denatured collagen type I through RGD sites. Biochem Biophys Res Commun 1992;182:1025-31.
16. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest 1997;100:S37-9.
17. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
18. 3 for angiogenesis. Science 1994;264:569-71.
19. Luscinskas FW, Lawler J. Integrins as dynamic regulators of vascular function. FASEB J 1994;8:929-38.
20. Kramer RH, Vu M, Cheng YF, Ramos DM. Integrin expression in malignant melanoma. Cancer Metastasis Rev 1991;10:49-59.
21. 3 integrin and the 92-kDa gelatinase in human HT-144 melanoma cell tumors grown in nude mice. Int J Cancer 1996;68:650-62.
22. v-integrins in tumour progression and metastasis. Semin Cancer Biol 1996;7:129-38.
23. 3-targeted magnetic resonance imaging. Nat Med 1998;4:623-6.
24. 3. Clin Cancer Res 2000;6:3056-61.
25. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
26. v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci U S A 1999;96:1591-6.
27. v integrin ligands improves its antineoplastic activity. Cancer Res 2004;64:565-71.
28. Dickerson EB, Akhtar N, Steinberg H, Arora A, Helfand SC. Peptide targeting of interleukin-12 to neovascular reduces its toxicity. J Immunother 2002;25:S17. Presented at the 17th Annual Meeting of the International Society for Biological Therapy of Cancer; November 7-10, 2002; La Jolla, CA.
29. Dickerson EB, Akhtar N, Steinberg H, Arora A, Helfand SC. Peptide targeting of interleukin-12 to neovascular reduces its toxicity. J Immunother 2002;25:S17. Presented at the 17th Annual Meeting of the International Society for Biological Therapy of Cancer; November 7-10, 2002; La Jolla, CA.
30. Lieschke GJ, Rao PK, Gately MK, Mulligan RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 1997;15:35-40.
31. v gene expression in human tumorigenicity. J Clin Invest 1992;89:2018-22.
32. Soiffer RJ, Robertson MJ, Murray C, Cochran K, Ritz J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 1993;82:2790-6.
33. Atkins MB, Robertson MJ, Gordon M, et al. Phase 1 evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
34. Robertson MJ, Cameron C, Atkins MB, et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 1999;5:9-16.
35. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83-243.
36. Coughlin CM, Wysocka M, Trinchieri G, Lee WM. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 1997;57:2460-7.
37. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M. Inhibition of the α-v integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumors in vivo. Br J Cancer 2002;86:788-95.
38. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy from spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997;89:1586-94.
39. Colombo MP, Vagliani M, Spreafico F, et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996;56:2531-4.
40. Duda DG, Sunamura M, Lozonschi L, et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000;60:1111-6.
41. Strasly M, Cavallo F, Geuna M, et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 2001;166:3890-9.
42. Peng LS, Penichet ML, Dela Cruz JS, Sampogna SL, Morrison SL. Mechanisms of antitumor activity of single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3). J Interferon Cytokine Res 2001;21:709-20.
43. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002;20:264-9.
44. 3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999;18:882-92.
45. 1-integrin- linked protein kinase. Nature 1996;379:91-6.
46. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A 1998;95:11211-6.
47. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. J Biol Chem 1998;273:30336-43.
48. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted proapoptotic peptides. Nat Med 1999;5:1032-8.
49. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 2001;40:2373-8.
50. Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994;54:182-9.
51. Okada Y, Okada N, Mizuguchi H, et al. Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochim Biophys Acta 2004;1670:172-80.
52. Clark KD, Volkman BF, Thoetkiattikul H, Hayakawa Y, Strand MR. N-terminal residues of plasmatocyte-spreading peptide possess specific determinants required for biological activity. J Biol Chem 2001;276:37431-5.
53. Schoenhaut DS, Chua AO, Wolitzky AG, et al. Cloning and expression of murine IL-12. J Immunol 1992;148:3433-40.
54. Helfand SC, Dickerson EB, Munson KL, Padilla ML. GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12. Cancer Res 1999;59:3119-27.
55. Teng J, Wang Z-Y, Bjorling DE. Estrogen-induced proliferation of urothelial cells is modulated by nerve growth factor. Am J Physiol Renal Physiol 2002;282: F1075-83.